SEC Form 4 · accession 0001562180-19-000853
Syndax Pharmaceuticals Inc · SNDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael L. Meyers
Officer — SVP, Chief Medical Officer
Period of report
Feb 6, 2019
Accepted (ET)
Feb 8, 2019 · 4:27 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001395937
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 31, 2019 | J | 3,720 | $4.76 | A | 6,118 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $6.38 | Feb 6, 2019 | A | 104,325 | A | — | Feb 6, 2029 | Common Stock | 104,325 | 104,325 | D |
Explanation of responses
- F1The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 3,720 shares by the Reporting Person on 01/31/2019 pursuant to the Issuer's Employee Stock Purchase Plan.
- F2The securities awarded on 02/06/2019 were in the form of stock options issued pursuant to the Syndax Pharmaceuticals, Inc. 2015 Omnibus Incentive Plan. Options to purchase 50,825 shares of common stock shall vest in 48 successive equal monthly installments measured from 02/06/2019. Options to purchase 53,500 shares of common stock shall vest periodically upon the Issuer achieving certain milestones.